Riskpilot← Back to searchSign inGet full accessSTIPE Therapeutics ApS
APSBankruptCVR 39691175Axeltorv 2Research and experimental development on natural sciences and engineering · NACE 7210Est. 20181 employees
Revenue 2024
DKK -842K
-76% vs 2023
EBITDA margin
178.1%
+70% vs 2023
Equity ratio
96.8%
Financial strength
Net profit 2024
DKK 1,4M
+133% vs 2023
| Revenue | DKK -842K | -76% |
| EBITDA | DKK -1,5M | +70% |
| Net profit | DKK 1,4M | +133% |
| Total assets | DKK 1,1M | -65% |
| Equity | DKK 1,1M | +144% |
| Employees | 1 | — |
Legal name
STIPE Therapeutics ApS
CVR number
39691175
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
2. juli 2018
Share capital
DKK 259.314
Employees
1 (FTE)
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er udvikling og kommercialisering af lægemidler og hermed forbundet virksomhed.
Address
Axeltorv 2
Email
prj@gorrissenfederspiel.com
- Event
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -1.331 | -2.949 | -4.087 | -6.588 | -3.457 | -842 |
| Staff expenses | -740 | -1.608 | -1.991 | -2.221 | -1.501 | -657 |
| EBITDA | -2.071 | -4.557 | -6.077 | -8.809 | -4.958 | -1.500 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -2.071 | -4.557 | -6.077 | -8.809 | -4.958 | -1.500 |
| Net financials | -82 | -47 | -144 | -200 | -235 | 2.949 |
| Profit before tax | -2.153 | -4.604 | -6.222 | -9.009 | -5.192 | 1.449 |
| Tax | -369 | -736 | -736 | -736 | -736 | -0 |
| Net profit | -1.784 | -3.868 | -5.485 | -8.273 | -4.456 | 1.449 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 8.048 | 4.625 | 14.511 | 6.202 | 3.218 | 1.124 |
| Equity | 6.689 | 3.764 | 10.232 | 1.959 | -2.497 | 1.088 |
| Long-term debt | 965 | 110 | 2.759 | 2.906 | 5.150 | 0 |
| Short-term debt | 394 | 750 | 1.521 | 1.337 | 565 | 36 |
| Total debt | 1.359 | 861 | 4.280 | 4.243 | 5.715 | 36 |
EBITDA margin
-149976400.0%
This company
15.8%
Market median
-949217822% vs market
20192024
Equity ratio
96.8%
This company
38.2%
Market median
+153% vs market
20192024
Return on equity
133.2%
This company
18.4%
Market median
+624% vs market
20192024
Net profit margin
144874800.0%
This company
8.1%
Market median
+1788577678% vs market
20192024
Asset turnover
-0.75×
This company
1.12×
Market median
-167% vs market
20192024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-07-02 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PJ Unofficial title | Unofficial title | 2024 | — | — |
CE Management | Management | 2018 | — | — |
MR Management | Management | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2019 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Novo Holdings A/S | Company | 25.0% | 25.0% | 2023 |
Sunstone Life Science Ventures Fund IV K/S | Company | 20.0% | 20.0% | 2023 |
| Individual | 20.0% | 20.0% | 2023 | |
MR Jakobsen Holding ApS | Company | 10.0% | 10.0% | 2021 |
CLAUS OLESEN HOLDING ApS | Company | 5.0% | 5.0% | 2021 |
| Individual | 20.0% | 20.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
STIPE Therapeutics ApS Board members of STIPE Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Preben Jakobsen | Unofficial title | 0 companies |
| Claus Elsborg Olesen | Management | 0 companies |
| Martin Roelsgaard Jakobsen | Management | 0 companies |
| Morten Døssing | Board of Directors | 0 companies |
| John Stephen Cassidy | Board of Directors | 0 companies |
| Christian Schetter | Chairman | 0 companies |
| Regina Hodits | Board of Directors | 0 companies |
| Mark David Chin | Board of Directors | 0 companies |
| Natalie Rose Sacks | Board of Directors | 0 companies |
| Sten Verland | Board of Directors | 0 companies |
| Jonathan Leslie Tobin | Board of Directors | 0 companies |